Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • OASIS 3

    - PMLiVE

    Medherant announces positive phase 1 results for testosterone patch for women

    University of Warwick spin-out develops first-in-class testosterone patch to support women through menopause

    - PMLiVE

    Innovation in Action at AAFP FMX 2025

    This year, Medscape Education is redefining the live learning experience at AAFP FMX 2025. With 8 groundbreaking, accredited symposia, we are proud to be at the heart of the meeting,...

    Medscape Education

    - PMLiVE

    Advertising For Women’s Health: Breaking Taboos and Driving Change

    Our strategist Stephanie Goley, MSc, PhD takes a fascinating look at how advertising is breaking down stigmas around areas of women's health such as menstruation and menopause - and helping...

    11 London

    Bayer symbol

    Bayer’s Kerendia granted FDA approval for new heart failure indication

    Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

    Bayer symbol

    Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours

    The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway

    - PMLiVE

    FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate

    The progressive neurodegenerative disease affects more than ten million people worldwide

    Bayer symbol

    Bayer UK launches digital educational hub to improve menopause support

    An estimated 13 million women in the UK are currently perimenopausal or menopausal

    Bayer symbol

    Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial

    Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy

    Bayer symbol

    Bayer presents positive results for Kerendia in late-stage heart failure study

    Approximately 55% of the 6.7 million heart failure patients in the US have an LVEF of at least 40%

    Bayer symbol

    Bayer and NextRNA Therapeutics enter oncology partnership worth $547m

    The companies will advance small molecule therapeutics against a new class of targets for cancer

    Bayer symbol

    Bayer shares promising results for Kerendia in phase 3 heart failure study

    Approximately 55% of heart failure patients have an LVEF of at least 40%

    Bayer symbol

    Bayer/Orion’s darolutamide combination shows promise in phase 3 prostate cancer trial

    The results from the study will support regulatory applications for wider use of the drug

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links